BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

325 related articles for article (PubMed ID: 9275002)

  • 21. The current status of docetaxel for metastatic breast cancer.
    Esteva FJ
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):17-26. PubMed ID: 12108894
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Phase III studies of single-agent docetaxel in patients with metastatic breast cancer who have progressed despite previous chemotherapy regimens: preliminary results.
    Nabholtz JM; Crown J
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):4-9. PubMed ID: 9865685
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Docetaxel in anthracycline-resistant metastatic breast cancer.
    Hui YF; Ignoffo RJ
    Cancer Pract; 1997; 5(2):124-7. PubMed ID: 9110651
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Taxoids in combination with epirubicin: the search for improved outcomes in breast cancer.
    Pagani O
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):23-6. PubMed ID: 9865708
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Docetaxel versus doxorubicin in patients with metastatic breast cancer who have failed alkylating chemotherapy: a preliminary report of the randomized phase III trial. 303 Study Group.
    Aapro M
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):7-11. PubMed ID: 9865705
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The efficacy of chemotherapy with docetaxel and paclitaxel in anthracycline-resistant breast cancer (Review).
    Pivot X; Asmar L; Hortobagyi GN
    Int J Oncol; 1999 Aug; 15(2):381-6. PubMed ID: 10402251
    [TBL] [Abstract][Full Text] [Related]  

  • 27. The international experience with docetaxel in the treatment of breast cancer.
    Ravdin PM
    Oncology (Williston Park); 1997 Mar; 11(3 Suppl 2):38-42. PubMed ID: 9110341
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Review of docetaxel (Taxotere), a highly active new agent for the treatment of metastatic breast cancer.
    Ravdin PM; Valero V
    Semin Oncol; 1995 Apr; 22(2 Suppl 4):17-21. PubMed ID: 7740326
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Recent progress in the clinical development of docetaxel (Taxotere).
    Hortobagyi GN
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):32-6. PubMed ID: 10426457
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Taxanes in combination with doxorubicin in the treatment of metastatic breast cancer.
    Dieras V
    Semin Oncol; 1998 Oct; 25(5 Suppl 12):18-22. PubMed ID: 9865707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Treatment of advanced breast cancer: current status.
    Piccart M
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():5-7. PubMed ID: 8862702
    [TBL] [Abstract][Full Text] [Related]  

  • 32. First-line treatment of metastatic breast cancer.
    Trudeau ME
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():9-12. PubMed ID: 8862703
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Taxoids in combination with anthracyclines and other agents: pharmacokinetic considerations.
    D'Incalci M; Schüller J; Colombo T; Zucchetti M; Riva A
    Semin Oncol; 1998 Dec; 25(6 Suppl 13):16-20. PubMed ID: 9865687
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Treatment of patients resistant to anthracycline therapy.
    Ravdin PM
    Anticancer Drugs; 1996 Aug; 7 Suppl 2():13-6. PubMed ID: 8862704
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Docetaxel (Taxotere) plus doxorubicin-based combinations: the evidence of activity in breast cancer.
    Nabholtz JM
    Semin Oncol; 1999 Jun; 26(3 Suppl 9):7-13. PubMed ID: 10426453
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Docetaxel: a review of its pharmacology and clinical activity.
    Trudeau ME
    Can J Oncol; 1996 Jun; 6(1):443-57. PubMed ID: 8853517
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Primary chemotherapy with docetaxel for the management of breast cancer.
    Valero V
    Oncology (Williston Park); 2002 Jun; 16(6 Suppl 6):35-43. PubMed ID: 12108896
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Docetaxel as single-agent therapy in metastatic breast cancer: clinical efficacy.
    Valero V
    Semin Oncol; 1997 Aug; 24(4 Suppl 13):S13-11-S13-18. PubMed ID: 9335512
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Docetaxel (Taxotere) in hormone-refractory prostate cancer.
    Petrylak DP
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):24-9. PubMed ID: 10810935
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Docetaxel (Taxotere) in HER-2-positive patients and in combination with trastuzumab (Herceptin).
    Burris HA
    Semin Oncol; 2000 Apr; 27(2 Suppl 3):19-23. PubMed ID: 10810934
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 17.